Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant

European Journal of Endocrinology

Volumn 149, Issue 6, 2003, Pages 521-527

  Drake, W M ^a,b   Rowles, S V ^a,b   Roberts, M E ^a,b   Fode, F K ^a,b   Besser, G M ^a,b   Monson, J P ^a,b   Trainer, P J ^a,b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FAT; FATTY ACID; GLUCOSE; INSULIN; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; BODY COMPOSITION; CARDIOVASCULAR DISEASE; CELL FUNCTION; CELL SECRETION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DOSE RESPONSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HUMAN; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; MALE; MEDICAL ASSESSMENT; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; TRANSSPHENOIDAL HYPOPHYSECTOMY; TREATMENT OUTCOME;

ACROMEGALY; ADULT; AGED; FEMALE; GLUCOSE TOLERANCE TEST; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; RECEPTORS, SOMATOTROPIN;

EID: 0346728594     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1490521     Document Type: Article

References (36)

1. Bates AS, Van't Hoff W, Jones JM & Clayton RN. An audit of outcome of treatment in acromegaly. Quarterly Journal of Medicine 1993 86 293-299.
2. Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism 1998 83 3419-3426.
3. Freda PU, Wardlaw SL & Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. Journal of Neurosurgery 1998 89 353-358.
4. Eastman RC, Gorden P & Roth J. Conventional supervoltage irradiation is an effective treatment for acromegaly. Journal of Clinical Endocrinology and Metabolism 1979 48 931-940.
5. Biermasz NR, van Dulken H & Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2000 85 2476-2482.
6. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. Journal of Clinical Endocrinology and Metabolism 1998 83 374-378.
7. Vance ML & Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analogue octreotide. Results of the International Multicenter Acromegaly Study Group. Archives of Internal Medicine 1991 151 1573-1578.
8. Flogstad AK, Halse J, Bakke S, Lancranjan I, Marbach P, Bruns C et al. Sandostatin LAR in acromegalic patients: long-term treatment. Journal of Clinical Endocrinology and Metabolism 1997 82 23-28.
9. Giusti M, Gussoni G, Cuttica CM & Giordano G. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group. Journal of Clinical Endocrinology and Metabolism 1996 81 2089-2097.
10. van der Lely A, Hutson R, Trainer P, Besser G, Barkan A, Katznelson L et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759.
11. Drake WM, Parkinson C, Besser GM & Trainer PJ. Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly. Trends in Endocrinology and Metabolism 2001 12 408-413.
12. Stewart PM. Pegvisomant: an advance in clinical efficacy in acromegaly. European Journal of Endocrinology 2003 148 S27-S32.
13. Ho KY, Jenkins D & Furler SM. Impact of a long acting somatostatin analogue octreotide on glucose tolerance and insulin sensitivity in acromegaly. Clinical Endocrinology 1992 36 271-279.
14. Koop BL, Harris AG & Ezzat S. Effect of octreotide on glucose tolerance in acromegaly. European Journal of Endocrinology 1994 130 581-586.
15. Gelding SV, Robinson S, Lowe S, Nithtananthan R & Johnston DG. Validation of the low dose short insulin tolerance test for evaluation of insulin sensitivity. Clinical Endocrinology 1994 40 611-615.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419.
17. Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clinical Endocrinology 2000 52 549-555.
18. Orme SM, McNally RJ, Cartwright RA & Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. Journal of Clinical Endocrinology and Metabolism 1998 83 2730-2734.
19. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK, Bates AS et al. Determinants of clinical outcome and survival in acromegaly Clinical Endocrinology 1994 41 95-102.
20. Davidson MB. Effect of growth hormone on carbohydrate and lipid metabolism. Endocrine Reviews 1987 8 115-131.
21. Rosenfeld RG, Wilson DM, Dollar LA, Bennett A & Hintz RL. Both human pituitary growth hormone and recombinant DNA-derived human growth hormone cause insulin resistance at a postreceptor site. Journal of Clinical Endocrinology and Metabolism 1982 54 1033-1038.
22. Rizza RA, Mandarino LJ & Gerich JE. Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance. impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes 1982 31 663-669.
23. Sonksen PH, Greenwood FH, Ellis JP, Lowey C, Rutherford A & Nabarro JDN. Changes of carbohydrate tolerance in acromegaly with the progress of the disease and its response to treatment. Journal of Clinical Endocrinology and Metabolism 1967 27 1418-1430.
24. Wass JAH, Cudworth AG, Bottazzo GF, Woodrow JC & Besser GM. An assessment of glucose intolerance in acromegaly and its response to medical treatment. Clinical Endocrinology 1980 12 53-59.
25. Moller N, Schmitz O & Jorgensen JOL. Basal and insulin stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. Journal of Clinical Endocrinology and Metabolism 1992 74 1012-1019.
26. Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M & Rizza R. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. American Journal of Physiology 1986 250 E269-E273.
27. DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J & Felber JP. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 1981 30 1000-1007.
28. Galbraith HJB, Ginsburg J & Paton A. Decreased response to intra-arterial insulin in acromegaly. Diabetes 1960 9 459-465.
29. Randle PJ, Garland PB, Hales CN & Newsholme EA. The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbance of diabetes mellitus. Lancet 1963 i 785-789.
30. Chen NY, Chen WY & Kopchick JJ. A growth hormone antagonist protects mice against streptozotocin induced glomerulosclerosis even in the presence of elevated levels of glucose and glycated hemoglobin. Endocrinology 1996 137 5163-5165.
31. Chen NY, Chen WY, Bellush L, Yang CW, Striker L, Striker GE et al. Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice. Endocrinology 1995 1362 660-667.
32. Mortimer CH, Carr D, Lind T, Bloom SR, Mallinson CN, Schally AV et al. Effects of growth hormone release-inhibiting hormone on circulating glucagon, insulin and growth hormone in normal, diabetic, acromegalic and hypopituitary patients. Lancet 1974 i 697-701.
33. Davies RR, Miller M, Turner SJ, Goodship TH, Cook DB, Watson M et al. Effects of somatostatin analogue SMS 201-995 in normal man. Clinical Endocrinology 1986 24 665-674.
34. McKnight JA, McCance DR, Crothers JG & Atkinson AB. Changes in glucose tolerance and development of gall stones during high dose treatment with octreotide for acromegaly. British Medical Journal 1989 299 604-605.
35. Parkinson C, Drake WM, Roberts ME, Meeran K, Besser GM & Trainer PJ. A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. Journal of Clinical Endocrinology and Metabolism 2002 87 1797-1804.
36. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. Journal of Clinical Endocrinology and Metabolism 2002 87 4554-4563.